Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REBRAnD2: TW-012R in Alzheimer's disease with presenilin 1 mutations
jRCT2041250040Phase 3Recruiting
- Sponsor
- Towa Pharmaceutical Co., Ltd.
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autosomal dominant Alzheimer's disease due to presenilin 1 mutation comparing TW-012R with Placebo (2 arms). Primary endpoint: SIB-J. Started Jun 2025; status: recruiting.
02
Drugs
TW-012R
03
Conditions
autosomal dominant Alzheimer's disease due to presenilin 1 mutation
Beyond the preview
Go deeper on jRCT2041250040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041250040.